Viewing StudyNCT05528458



Ignite Creation Date: 2024-05-06 @ 6:03 PM
Last Modification Date: 2024-10-26 @ 2:40 PM
Study NCT ID: NCT05528458
Status: RECRUITING
Last Update Posted: 2024-04-23
First Post: 2022-08-30

Brief Title: Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Sponsor: Samsung Medical Center
Organization: Samsung Medical Center

Organization Data

Organization: Samsung Medical Center
Class: OTHER
Study ID: 2022-05-063
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Samsung Medical Center
Lead Sponsor Class: OTHER
Responsible Party: Se-Hoon Lee
Responsible Party Title: Principle Investigator
Responsible Party Type: PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation: Samsung Medical Center
Old Name: None
Old Organization: None

Collaborators